halometasone
Small moleculeexperimental
Halometasone is a potent synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other regions such as China, Hong Kong, Turkey, Israel, South Africa and India. — Wikipedia
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Aug 1, 2015 (NCT03946826)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHalometasone ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03246776 | Phase 4 | Aug 20, 2017 | Capital Medical University |
| NCT03946826 | N/A | Aug 1, 2015 | China Medical University, Chinese Academy of Medical Sciences, People's Liberation Army of China, Xijing Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2015 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2015 |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2015 |
5 organizations
Page 1 / 1